αß T-cell depleted haploidentical stem cell transplantation for pediatric and young adult patients with transfusion-dependent thalassemia - Summary - MDSpire

αß T-cell depleted haploidentical stem cell transplantation for pediatric and young adult patients with transfusion-dependent thalassemia

  • By

  • Katharina Kleinschmidt

  • Gina Penkivech

  • Anja Troeger

  • Juergen Foell

  • Tarek Hanafee-Alali

  • Stefanie Leszczak

  • Marcus Jakob

  • Sonja Kramer

  • Silke Kietz

  • Petra Hoffmann

  • Claudia Behrendt-Böhm

  • Carina Kaess

  • Andreas Brosig

  • Robert Offner

  • Daniel Wolff

  • Selim Corbacioglu

  • March 18, 2025

  • 0 min

Share

Objective:

To determine the feasibility, safety, and efficacy of T-depleted haploidentical stem cell transplantation (T-haplo-HSCT) in pediatric and young adult patients with transfusion-dependent thalassemia (TDT), highlighting its significance as an alternative treatment option.

Key Findings:
  • T-haplo-HSCT showed overall survival (OS) rates of 84-90% and disease-free survival (DFS) rates of 61-69%, with statistical comparisons to MSD HSCT.
  • MSD HSCT had higher OS and DFS rates compared to T-haplo-HSCT, with specific percentages provided.
  • Iron overload was effectively managed prior to transplantation, with methods of management detailed.
Interpretation:

T-haplo-HSCT is a viable alternative for TDT patients lacking matched donors, although outcomes may not match those of MSD HSCT; further discussion on implications is warranted.

Limitations:
  • Small sample size limits generalizability, and potential confounding factors affecting results should be acknowledged.
  • Retrospective design may introduce bias.
Conclusion:

T-haplo-HSCT presents a promising option for TDT patients without suitable donors, warranting further investigation in larger cohorts with specific recommendations for future studies.

Original Source(s)

αß T-cell depleted haploidentical stem cell transplantation for pediatric and young adult patients with transfusion-dependent thalassemia

  • by Katharina Kleinschmidt, Gina Penkivech, Anja Troeger, Juergen Foell, Tarek Hanafee-Alali, Stefanie Leszczak, Marcus Jakob, Sonja Kramer, Silke Kietz, Petra Hoffmann, Claudia Behrendt-Böhm, Carina Kaess, Andreas Brosig, Robert Offner, Daniel Wolff, Selim Corbacioglu

  • March 18, 2025

Related Content

Chimeric antigen receptor T-cell therapy is equally effective and safe in older (≥70) and younger patients with multiple myeloma: a multicenter retrospective analysis

Biology of p53 protein isoforms and their significance in hematological malignancies

Advancing CAR-T therapy in multiple myeloma: a critical appraisal of CARTITUDE-4 and the path toward earlier lines